Gabapentin suppresses spasticity in the spinal cord-injured rat

Neuroscience

Volumn 149, Issue 4, 2007, Pages 813-821

  Kitzman, P H ^a   Uhl, T L ^a   Dwyer, M K ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

muscle hyperreflexia; presynaptic glutamate inhibition

Indexed keywords

GABAPENTIN; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; ELECTROMYOGRAPHY; ELECTROPHYSIOLOGY; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPASTICITY; SPINAL CORD INJURY;

AMINES; ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; CROSS-OVER STUDIES; CYCLOHEXANECARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; ELECTROMYOGRAPHY; FEMALE; GAMMA-AMINOBUTYRIC ACID; MUSCLE SPASTICITY; RATS; RATS, SPRAGUE-DAWLEY; REFLEX, ABNORMAL; SPINAL CORD INJURIES; TIME FACTORS;

EID: 36249031078     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2007.07.020     Document Type: Article

References (53)

1. Abbruzzee G. The medial management of spasticity. Eur J Neurol 9 (2002) 53-61
2. Alvarez F.J., Villalba R.M., Zerda R., and Schneider S.P. Vesicular glutamate transporters in the spinal cord, with special reference to sensory primary afferent synapses. J Comp Neurol 472 (2004) 257-280
3. Bennett D.J., Gorassini M., Fouad K., Sanelli L., Han Y., and Cheng J. Spasticity in rats with sacral spinal cord injury. J Neurotrauma 16 (1999) 69-83
4. Bennett D.J., Sanelli L., Cooke C.L., Harvey P.J., and Gorassini M.A. Spastic long-lasting reflexes in the awake rat after sacral spinal cord injury. J Neurophysiol 91 (2004) 2247-2258
5. Benoit D.L., Lamontagne M., Cerulli G., and Liti A. The clinical significance of electromyography normalization techniques in subjects with anterior cruciate ligament injury during treadmill walking. Gait Posture 18 (2003) 56-63
6. Burden A., and Bartlett R. Normalisation of EMG amplitude: an evaluation and comparison of old and new methods. Med Eng Physics 21 (1999) 247-257
7. Burden A.M., Trew M., and Baltzopoulos V. Normalisation of gait EMGs: a re-examination. J Electromyogr Kinesiol 13 (2003) 519-532
8. Burridge J.H., Wood D.E., Hermens H.J., Voerman G.E., Johnson G.R., Van Wijck F., Platz T., Gregoric M., Hitchcock R., and Pandyan A.D. Theoretical and methodological considerations in the measurement of spasticity. Disabil Rehabil 27 (2005) 69-80
9. Coderre T.J., Kumar N., Lefebvre C.D., and Yu J.S.C. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 94 (2005) 1131-1139
10. Coderre T.J., Kumar N., Lefebvre C.D., and YU J.S.C. A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. J Neurochem 100 (2007) 1289-1299
11. Crawford P., Ghadiali E., Lane R., Blumhardt L., and Chadwick D. Gabapentin as an antiepileptic drug in man. J Neurology Neurosurg Psychiatry 50 (1987) 682-686
12. Cutter N.C., Scott D.D., Johnson J.C., and Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial. Arch Phys Med Rehabil 81 (2000) 164-169
13. De Vry J., Kuhl E., Franken-Kunkel P., and Eckel G. Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur J Pharmacol 491 (2004) 137-148
14. Elovic E. Principles of pharmaceutical management of spastic hypertonia. Arch Med Rehabil Clin North Am 12 (2001) 793-816
15. Francisco G.G., Kothari S., and Huls C. GABA agonist and gabapentin for spastic hypertonia. Phys Med Rehabil 12 (2001) 875-888
16. Gaida W., Klinder K., Arndt K., and Weiser T. Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain syndromes in animal models of chronic, neuropathic and inflammatory pain. Neuropharmacology 49 (2005) 1220-1227
17. Gatti G., Ferrari A.R., Guerrini R., Bonanni P., Bonomi I., and Perucca E. Plasma gabapentin concentration n children with epilepsy: Influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. Ther Drug Monitor 25 (2003) 54-60
18. Goa K.L., and Sorkin E.M. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs 46 (1993) 409-427
19. Gruenthal M., Mueller M., Olson W.L., Priebe M.M., Sherwood A.M., and Olson W.H. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord 35 (1997) 686-689
20. Hebel R., and Stromberg M.W. Anatomy of the laboratory rat (1976), Williams & Wilkins, Baltimore
21. Hofmann H.A., De Vry J., Siegling A., Spreyer P., and Denzer D. Pharmacological sensitivity and gene expression analysis of the tibial nerve injury model of neuropathic pain. Eur J Pharmacol 470 (2003) 17-25
22. Kirshblum S. Treatment alternatives for spinal cord injury related spasticity. J Spinal Cord Med 22 (1999) 199-217
23. Kitzman P.H. Alteration in axial motoneuronal morphology in the spinal cord injured spastic rat. Exp Neurol 192 (2005) 100-108
24. Kitzman P.H. Changes in vesicular glutamate transporter 2, vesicular GABA transporter and vesicular acetylcholine transporter labeling of sacrocaudal motoneurons in the spastic rat. Exp Neurol 197 (2006) 407-419
25. Kitzman P.H. VGLUT1 and GlyT2 labeling of sacrocaudal motoneurons in the spinal cord injured spastic rat. Exp Neurol 204 (2007) 195-204
26. LaBuda C.J., and Little P.J. Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat. J Neurosci Methods 144 (2005) 175-181
27. Landry M., Bouali-Benazzouz R., Mestikawy S.E., Ravassard P., and Nagy F. Expression of vesicular glutamate transporters in rat lumbar spinal cord, with a note on the dorsal horn. J Comp Neurol 468 (2004) 380-394
28. Levendoǧlu F., Öǧün C.O., Özerbil Ö., Öǧün T.C., and Uǧurlu H. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine 29 (2004) 743-751
29. Maneuf Y.P., and McKnight A.T. Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol 134 (2001) 237-240
30. + evoked release of [3H]-glutamate from the caudal trigeminal nucleus of the streptozotocin-treated rat. Br J Pharmacol 141 (2004) 574-579
31. Mayer N.H. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve Suppl 6 (1997) S1-S13
32. McLean M.J. Clinical pharmacokinetics of gabapentin. Neurology 22 (1994) S17-S22
33. McLean M.J. Gabapentin. Epilepsia 36 (1995) S73-S86
34. McLean M.J., Morrell M.J., Willmore J.L., Privitera M.D., Faught E.R., Holmes G.L., Magnus-Miller L., Bernstein P., and Rose-Legatt A. Safety and tolerability of gabapentin as adjunctive therapy in a large multicenter study. Epilepsia 40 (1999) 965-972
35. McLean M.J., and Gidal B.E. Gabapentin dosing in the treatment of epilepsy. Clin Ther 25 (2003) 1382-1406
36. Morello C.M., Leckband S.G., Stoner C.P., Moorhouse D.F., and Sahagian G.A. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 159 (1999) 1931-1937
37. Mueller M.E., Gruenthal M., Olson W.L., and Olson W.H. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil 78 (1997) 521-524
38. Oliveira A.L.R., Hydling F., Olsson E., Shi T., Edwards R.H., Fujiyama F., Kaneko T., Hokfelt T., Cullheim S., and Meister B. Cellular localization of three vesicular glutamate transporter mRNA and proteins in rat spinal cord and dorsal root ganglia. Synapse 50 (2003) 117-129
39. Pandyan A.D., Gregoric M., Barnes M.P., Wood D., Van Wijck F., Burridge J., Hermens H., and Johnson G.R. Spasticity: Clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil 27 (2005) 2-6
40. Pedersen L.H., and Blackburn-Munro G. Pharmacological characterization of place escape/avoidance behavior in the rat chronic constriction injury model of neuropathic pain. Psychopharmacology 185 (2006) 208-217
41. Platz T., Eickhof C., Nuyens G., and Vuadens P. Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature. Disabil Rehabil 27 (2005) 7-18
42. Priebe M.M., Sherwood A.M., Graves D.E., Mueller M., and Olson W.H. Effectiveness of gabapentin in controlling spasticity: a quantitative study. Spinal Cord 35 (1997) 171-175
43. Proulx N.L., Drolet G.L., and Laramee M.T. Secondary impairments after spinal cord injury: A population-based study. Am J Phys Med Rehabil 79 (2000) 526-535
44. Ritz L.A., Friedman R.M., Rhoton E.L., Sparkes M.L., and Vierck Jr. C.L. Lesions of cat sacrocaudal spinal cord: a minimally disruptive model of injury. J Neurotrauma 9 (1992) 219-230
45. Rowbotham M., Harden N., Stacey B., Bernstein P., and Magnus-Miller L. Gabapentin for the treatment of postoperative neuralgia: a randomized controlled trial. JAMA 280 (1998) 1837-1842
46. Shimoyama M., Shimayama N., and Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain 85 (2000) 405-414
47. Sköld C., Levi R., and Seiger A. Spasticity after traumatic spinal cord injury: nature, severity, and location. Arch Phys Med Rehabil 80 (1999) 1548-1557
48. Soni B.M., Mani R.M., Oo T., and Vaidyanathan S. Treatment of spasticity in a spinal cord- injured patient with intrathecal morphine due to intrathecal baclofen tolerance: a case report and review of literature. Spinal Cord 41 (2003) 586-589
49. Taricco M., Adone R., Pagliacci C., and Telaro E. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst Rev 2 (2000) CD001131
50. Todd A.J., Hughes D.I., Polgar E., Nagy G.G., Mackie M., Ottersen O.P., and Maxwell D.J. The expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in neurochemically defined axonal populations in the rat spinal cord with emphasis on the dorsal horn. Eur J Neurosci 17 (2003) 13-27
51. Walter J.S., Sacks J., Othman R., Rankin A.Z., Nemchausky B., Chintam R., and Wheeler J.S. A database of self-reported secondary medical problems among VA spinal cord injury patients: its role in clinical care and management. J Rehabil Res Dev 39 (2002) 53-61
52. Wheeler G. Gabapentin. Pfizer. Curr Opin Investig Drugs 3 (2002) 470-477
53. Wood D.E., Burridge J.H., Van Wijck F.M., McFadden C., Hitchcock R.A., Pandyan A.D., Salazar-Torres J.J., and Swain I.D. Biomechanical approaches applied to the lower and upper limb for the measurement of spasticity: A systematic review of the literature. Disabil Rehabil 27 (2005) 19-32